AR083020A1 - Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden - Google Patents

Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden

Info

Publication number
AR083020A1
AR083020A1 ARP110103392A ARP110103392A AR083020A1 AR 083020 A1 AR083020 A1 AR 083020A1 AR P110103392 A ARP110103392 A AR P110103392A AR P110103392 A ARP110103392 A AR P110103392A AR 083020 A1 AR083020 A1 AR 083020A1
Authority
AR
Argentina
Prior art keywords
imidazol
methylphenyl
methanol
prepare
pharmaceutical composition
Prior art date
Application number
ARP110103392A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR083020A1 publication Critical patent/AR083020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de un compuesto de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol que tiene la fórmula (1), (2) ó (3), sus enantiómeros individuales, sus diastereoisómeros, sus hidratos, sus solvatos, sus formas cristalinas, sus isómeros individuales, sus tautómeros individuales o una sal farmacéuticamente aceptable de la misma, donde R1 es H o alquilo C1-3; R2 es H o alquilo C1-3; R3 es H, alquilo C1-10, heterociclo o arilo; y R es alquilo C1-10, heterociclo o arilo; para preparar un medicamento útil para tratar las enfermedades de la piel y las afecciones de la piel. Artículo de fabricación y composición farmacéutica que comprenden dicho compuesto.
ARP110103392A 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden AR083020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16

Publications (1)

Publication Number Publication Date
AR083020A1 true AR083020A1 (es) 2013-01-23

Family

ID=44675870

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP110103392A AR083020A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103391A AR083019A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103389A AR083017A1 (es) 2010-09-16 2011-09-16 Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
ARP110103390A AR083018A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP110103391A AR083019A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103389A AR083017A1 (es) 2010-09-16 2011-09-16 Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
ARP110103390A AR083018A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden

Country Status (29)

Country Link
US (9) US8492422B2 (es)
EP (13) EP3050563B1 (es)
JP (4) JP6073229B2 (es)
KR (7) KR101840501B1 (es)
CN (5) CN105412092B (es)
AR (4) AR083020A1 (es)
AU (4) AU2011301847B2 (es)
BR (4) BR112013006355A2 (es)
CA (8) CA3116249A1 (es)
CL (4) CL2013000735A1 (es)
CY (3) CY1121024T1 (es)
DK (9) DK3050563T3 (es)
ES (10) ES2613509T3 (es)
HK (5) HK1185538A1 (es)
HU (5) HUE039090T2 (es)
IL (4) IL225281A0 (es)
MX (4) MX2013003009A (es)
MY (4) MY161607A (es)
NZ (1) NZ608751A (es)
PL (7) PL3053576T3 (es)
PT (7) PT3338777T (es)
RU (4) RU2612351C2 (es)
SG (4) SG188572A1 (es)
SI (5) SI3338777T1 (es)
TR (1) TR201909249T4 (es)
TW (4) TWI591058B (es)
UA (1) UA112973C2 (es)
WO (4) WO2012037490A1 (es)
ZA (4) ZA201302193B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733905T3 (es) * 2009-02-13 2019-12-03 Allergan Inc Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
EP2734200A1 (en) * 2011-07-22 2014-05-28 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
JP2021534250A (ja) * 2018-08-24 2021-12-09 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッドAdlai Nortye Biopharma Co., Ltd. 高活性ｓｔｉｎｇタンパク質アゴニスト
KR20230172529A (ko) * 2021-04-16 2023-12-22 에이디에스 테라퓨틱스 엘엘씨 무스칼린 작용제 약물과 접합된 알파2 아드레날린 작용제 복합 약물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3631490B2 (ja) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
EP1638943B1 (fr) * 2003-05-27 2008-08-06 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) NOUVEAUX DERIVES D’IMIDAZOLES, LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENT
CN1823518A (zh) * 2003-07-14 2006-08-23 皇家飞利浦电子股份有限公司 投影设备
CA2538445A1 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
NZ552325A (en) 2004-05-25 2010-11-26 Sansrosa Pharmaceutical Dev Inc The use of alpha 2 andrenoceptor agonists such as brimonidine for treating inflammatory skin disorders
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
RU2383535C2 (ru) 2004-09-24 2010-03-10 Аллерган, Инк. 4-(фенилметил и замещенный-фенилметил)-имидазол-2-тионы, действующие как специфические альфа2-адренергические агонисты
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
EP2393800B1 (en) 2009-02-06 2014-10-08 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
ES2733905T3 (es) 2009-02-13 2019-12-03 Allergan Inc Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

Also Published As

Publication number Publication date
CN103200941A (zh) 2013-07-10
CY1122809T1 (el) 2021-05-05
ES2760920T3 (es) 2020-05-18
PL3053576T3 (pl) 2018-11-30
US8501796B2 (en) 2013-08-06
DK3050564T3 (da) 2019-11-25
US20120122945A1 (en) 2012-05-17
PL3050563T3 (pl) 2018-12-31
CA3122745A1 (en) 2012-03-22
EP3050564B1 (en) 2019-09-04
EP2616066A1 (en) 2013-07-24
ZA201302193B (en) 2013-11-27
PT2616068T (pt) 2016-09-13
SI3050564T1 (sl) 2020-02-28
KR101952457B1 (ko) 2019-02-26
US8492557B2 (en) 2013-07-23
IL225282A0 (en) 2013-06-27
EP3050563A1 (en) 2016-08-03
DK3348264T3 (da) 2020-03-23
UA112973C2 (uk) 2016-11-25
KR20130114140A (ko) 2013-10-16
ES2904479T3 (es) 2022-04-05
WO2012037499A1 (en) 2012-03-22
HK1257416A1 (zh) 2019-10-18
EP3050563B1 (en) 2018-05-09
RU2013116541A (ru) 2014-10-27
KR102139905B1 (ko) 2020-07-31
PL3348264T3 (pl) 2020-08-24
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
EP2616067A1 (en) 2013-07-24
TWI591058B (zh) 2017-07-11
CL2013000734A1 (es) 2013-11-08
DK3338777T3 (da) 2020-04-20
HUE039090T2 (hu) 2018-12-28
CN103200942A (zh) 2013-07-10
CA3079450A1 (en) 2012-03-22
WO2012037484A1 (en) 2012-03-22
WO2012037490A1 (en) 2012-03-22
JP2013537236A (ja) 2013-09-30
US20160354346A1 (en) 2016-12-08
US20140057958A1 (en) 2014-02-27
TW201240661A (en) 2012-10-16
AU2011301856A1 (en) 2013-05-02
EP3078376A1 (en) 2016-10-12
ES2607084T3 (es) 2017-03-29
CA2812197A1 (en) 2012-03-22
CA2812191C (en) 2021-04-13
MX2013003008A (es) 2013-06-28
EP2616067B1 (en) 2016-05-18
ES2593612T3 (es) 2016-12-12
HK1185538A1 (zh) 2014-02-21
EP3348264B1 (en) 2020-01-01
EP3338777B1 (en) 2020-02-05
US8492422B2 (en) 2013-07-23
EP3053576A1 (en) 2016-08-10
CY1122958T1 (el) 2021-10-29
CN103200941B (zh) 2015-12-16
JP2013540749A (ja) 2013-11-07
US8853251B2 (en) 2014-10-07
TW201305116A (zh) 2013-02-01
EP2616066B1 (en) 2016-07-13
AU2011301856C1 (en) 2016-09-08
EP3078376B1 (en) 2019-03-27
SI3348264T1 (sl) 2020-07-31
MX2013003004A (es) 2013-06-28
US20120142746A1 (en) 2012-06-07
PT3050564T (pt) 2019-12-11
AU2011301901B2 (en) 2016-02-11
AU2011301932B2 (en) 2016-02-25
KR20140003407A (ko) 2014-01-09
EP3659600A1 (en) 2020-06-03
EP2616068B1 (en) 2016-07-13
HK1185540A1 (zh) 2014-02-21
SG188571A1 (en) 2013-04-30
AU2011301932A1 (en) 2013-05-02
US8653123B2 (en) 2014-02-18
CL2013000735A1 (es) 2013-11-29
MY173846A (en) 2020-02-24
MY168763A (en) 2018-12-04
KR102104760B1 (ko) 2020-04-27
US20120149746A1 (en) 2012-06-14
NZ608751A (en) 2015-04-24
KR20190022895A (ko) 2019-03-06
DK2616068T3 (en) 2016-08-29
KR101840500B1 (ko) 2018-03-20
CA2812191A1 (en) 2012-03-22
PL3050564T3 (pl) 2020-06-01
ES2781681T3 (es) 2020-09-04
CN103221045A (zh) 2013-07-24
EP2616069A1 (en) 2013-07-24
PL2616069T3 (pl) 2017-04-28
AR083018A1 (es) 2013-01-23
TW201305117A (zh) 2013-02-01
CA3077732A1 (en) 2012-03-22
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
BR112013006352A2 (pt) 2016-06-28
EP2616069B1 (en) 2016-11-16
IL225280A0 (en) 2013-06-27
BR112013006320A2 (pt) 2016-06-21
MY161607A (en) 2017-04-28
TW201240662A (en) 2012-10-16
PT3348264T (pt) 2020-04-02
EP3338777A1 (en) 2018-06-27
DK3050563T3 (en) 2018-08-13
DK3078376T3 (da) 2019-06-24
SG188573A1 (en) 2013-04-30
HK1185541A1 (zh) 2014-02-21
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
MX2013003002A (es) 2013-06-28
JP2013541527A (ja) 2013-11-14
DK2616069T3 (en) 2016-12-19
MY191369A (en) 2022-06-20
WO2012037453A1 (en) 2012-03-22
DK3636263T3 (da) 2022-01-10
CA2812197C (en) 2024-01-02
US20130296394A1 (en) 2013-11-07
US20130289088A1 (en) 2013-10-31
EP3050564A1 (en) 2016-08-03
SI3338777T1 (sl) 2020-08-31
US20150148394A1 (en) 2015-05-28
PT3050563T (pt) 2018-10-01
SG188572A1 (en) 2013-04-30
AU2011301901A1 (en) 2013-05-02
KR20200091507A (ko) 2020-07-30
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
EP3636263A1 (en) 2020-04-15
AU2011301847A1 (en) 2013-05-02
HUE048725T2 (hu) 2020-09-28
CA2811559A1 (en) 2012-03-22
PT3338777T (pt) 2020-05-06
BR112013006355A2 (pt) 2016-06-28
MX2013003009A (es) 2013-06-28
ES2737230T3 (es) 2020-01-10
PT2616069T (pt) 2016-12-06
US20120136036A1 (en) 2012-05-31
JP6045495B2 (ja) 2016-12-14
PL3338777T3 (pl) 2020-07-13
ES2684055T3 (es) 2018-10-01
RU2013116405A (ru) 2014-10-27
AR083019A1 (es) 2013-01-23
EP3348264A1 (en) 2018-07-18
BR112013006320B1 (pt) 2022-08-30
CY1121024T1 (el) 2019-12-11
JP6073229B2 (ja) 2017-02-01
IL225278A0 (en) 2013-06-27
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
PT3053576T (pt) 2018-10-08
EP3698789A1 (en) 2020-08-26
HUE047476T2 (hu) 2020-04-28
HUE038698T2 (hu) 2018-11-28
SG188570A1 (en) 2013-04-30
HUE049573T2 (hu) 2020-10-28
ES2788051T3 (es) 2020-10-20
DK3053576T3 (en) 2018-08-20
ZA201302288B (en) 2013-11-27
KR20200044147A (ko) 2020-04-28
KR101840501B1 (ko) 2018-05-04
HK1185539A1 (zh) 2014-02-21
RU2612351C2 (ru) 2017-03-07
CN105412092A (zh) 2016-03-23
CN105412092B (zh) 2020-11-17
ZA201302194B (en) 2013-11-27
SI3050563T1 (sl) 2018-10-30
CA3116249A1 (en) 2012-03-22
CL2013000733A1 (es) 2013-08-23
AU2011301932C1 (en) 2016-09-01
EP2616068A1 (en) 2013-07-24
EP3053576B1 (en) 2018-05-16
SI3053576T1 (sl) 2018-11-30
ES2687420T3 (es) 2018-10-25
PL2616068T3 (pl) 2016-11-30
TR201909249T4 (tr) 2019-07-22
EP3636263B1 (en) 2021-11-03
RU2013116403A (ru) 2014-10-27
AU2011301847B2 (en) 2016-02-11
CL2013000736A1 (es) 2013-07-12
CA2812195A1 (en) 2012-03-22
CN103209694A (zh) 2013-07-17
KR102354097B1 (ko) 2022-01-20

Similar Documents

Publication Publication Date Title
AR083020A1 (es) Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AU2008245082A8 (en) Aminodihydrothiazine derivatives substituted with a cyclic group
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
NZ591728A (en) Cephalosporin having catechol group
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
AR078522A1 (es) Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR109224A2 (es) Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
IN2012DN02502A (es)
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
ECSP22083772A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
BR112012017845A2 (pt) novo processo para produção de derivados de benzofenona
WO2010132670A3 (en) Pentacycline compounds
PH12020551340A1 (en) Methyllactam ring compound and pharmaceutical use thereof
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
BR112012020060B8 (pt) uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
AR063924A1 (es) Analogos de pirazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure